Orthox is a self-described leading medical device company that develops treatments for injuries to cartilage and other hard-to-heal human tissues.

Orthox

Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated.  Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. 

Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™  achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints.

Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and is currently undergoing evaluation through the FFLEX clinical study being run at major hospitals across Europe. FibroFix™ technology will then be rolled out to treat damaged cartilage in other joints while pipeline products beyond orthopaedics in which the application of great strength and tissue regeneration are key will also be developed.

Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment.

Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.

EIT Health

National Institute for Health Research

Innovate UK

EASME - EU Executive Agency for SMEs

Additio Investment Group

Oxford Investment Consultants LLP

Parkwalk Advisors

Perivoli Innovations

AtmosClear Investments

ORTHOX LIMITED

We are delighted to announce that we have received a “Letter of No Objection” from the UK’s MHRA, enabling the start of our “FFLEX Study” (derived from the “FibroFix cartiLage repair Experience”). This important clinical trial will assess the safety and performance of our FibroFix™ Cartilage implant and accessory surgical instrumentation in the knee joints of patients suffering with cartilage injuries. 
Patient recruitment is expected to open this month at our lead clinical site, Southmead Hospital, Bristol, UK.
We have also received grant of key patents in the US, China, the UK, Germany, and France providing long term protection for our FibroFix™ implant platform in these major global economies.
 #mhra #patents #cartilage #knee #medtech

ORTH

COM:ORTHOX

Orthox